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A B S T R A C T
The metabolic syndrome, characterized by obesity, dyslipidemia, insulin resistance 
and hypertension, increases the risk of cardiovascular morbidity and mortality. In re-
cent years, the convergence of evidence from several studies has resulted in a major 
shift both in the understanding of the pathophysiology and the treatment options for 
this disease. Shunning away from the glucocentric hypothesis, this is now based on 
a unified ‘lipotoxicity’ hypothesis, according to which metabolic syndrome and type 
2 diabetes mellitus can be caused by the ectopic accumulation of triglycerides and 
long-chain fatty acids in liver, muscle and pancreatic islets. This lipocentric approach 
is integrated with the analysis of inflammatory reactions associated with end-organ 
damage, including the vascular wall. Transcription factors and coactivators, includ-
ing peroxisome proliferator-activated receptor coactivator-1 are crucial in mediating 
insulin resistance and accelerating vascular wall inflammation, and represent prom-
ising therapeutic targets. This new integrated view of the metabolic syndrome also 
takes into account the genetic differences among individuals and consequent variant 
response to therapy.
I N T R O D U C T I O N
The metabolic syndrome, characterized by obesity, dyslipidemia, insulin resist-
ance and hypertension, contributes to early atherosclerosis and increases the risk of 
cardiovascular morbidity and mortality.1,2 Unfortunately its prevalence starts early in 
life; in the period between 1999 and 2002, the prevalence rate of metabolic syndrome 
in US adolescents varied overall from just >9% to as low as 2%.3 Most current views 
on the pathogenesis of the metabolic syndrome and its existing treatments have been 
dominated by a glucocentric approach: the glycemic response to insulin is subop-
timal, with dire metabolic consequences.4-6 Such consequences are compensatory 
hyperinsulinemia, β cell glucotoxicity and lipotoxicity and the deposition of amyloid 
in pancreatic islets, with concomitant inflammation, endothelial dysfunction, a 
procoagulant state and dyslipidemia. In addition, these views have been applied on 
the premise that effector molecules involved in disease pathogenesis or response to 
therapy are invariant across the population. However, most current therapies have 
limited efficacy and limited tolerability.
EDITORIAL
Department of Pharmacology, Patras 
University School of Medicine, Patras, 
Greece
HOSPITAL CHRONICLES 2008, 3(3): 105–106
Correspondence to:
Christodoulos Flordellis, MD
Professor & Director of Pharmacology
Patras University School of Medicine
Patras, Greece
E-mail: flordell@med.upatras.gr
KEY WORDS: metabolic syndrome; 
obesity; insulin resistance; diabetes; 
hypertriglyceridemia; hypertension
LIST OF ABBREVIATIONS: 
IL-6 = interleukin 6
MMPs = metaloproteinases
PPARγ = peroxisome proliferator-
activated receptor γ
TNF-α = tumor necrosis factor α
Presented in part at “Cardiology Update 2006”, International Cardiology Symposium of Evagelismos General Hospital of Athens, Athens, 
Greece, April 13-15, 2006
106
HOSPITAL CHRONICLES 3(3), 2008
“ L I P O T O X I C I T Y ”  H Y P O T H E S I S  A N D 
P R O - I N F L A M M A T O R Y  M A R K E R S
In recent years, the convergence of evidence from several 
studies has resulted in a major shift both in the understand-
ing of the pathophysiology and the treatment options for this 
disease. This is based on a unified ‘lipotoxicity’ hypothesis, 
according to which metabolic syndrome and type 2 diabetes 
mellitus can be caused by the ectopic accumulation of triglyc-
erides and long-chain fatty acids in liver, muscle and pancreatic 
islets. Similar lipid changes in selective hypothalamic neurons 
regulate insulin action and glucose homeostasis, in addition to 
food intake and body weight. This lipocentric approach is inte-
grated with the analysis of inflammatory reactions associated 
with end-organ damage, including that in the vascular wall.5-14 
The integration of inflammatory and metabolic mechanisms 
in obesity is based on the functional overlap of macrophages 
and adipocytes. The latter reflects the plasticity of macrophage 
and pre-adipocyte. Adipocytes produce inflammatory “mac-
rophage” proteins such as tumor necrosis factor α (TNF-α), 
interleukin 6 (IL-6) and metaloproteinases (MMPs).8,9 In 
addition adipokines, such as adiponectin, resistin and visfatin 
have immunological activity along with metabolic functions. 
Moreover, lipids themselves exert inflammatory and metabolic 
actions through lipid-targeted pathways via nuclear receptors. 
Meanwhile macrophages express peroxisome proliferator-
activated receptor γ (PPARγ).10-13
Transcription factors and coactivators, including PPARγ 
coactivator-1, are crucial in mediating insulin resistance 
and accelerating vascular wall inflammation, and represent 
promising therapeutic targets. New pharmacological strategies 
include dual PPARα/γ agonists, drugs with pleiotropic effects 
or combination therapies.11-16
G E N O M I C S
Finally, the application of genomic and proteomic method-
ologies in animal models of diabetes, and in serum and tissues 
from normal individuals and patients with type 2 diabetes mel-
litus, has identified clusters of genes and proteins that might 
contribute to cardinal aspects of this disease such as insulin 
resistance, β cell dysfunction and vascular wall damage.16-18 
The new integrated view of the metabolic syndrome takes into 
account the genetic differences among individuals when the 
clinical heterogeneity of the clinical phenotypes or variation 
of the response to therapy is considered.
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